Gilead Declines After HIV Patent Fight Loss, China IP Interest

(Bloomberg) -- Gilead Sciences Inc. shares fell Wednesday after the drugmaker was rebuffed in its effort to invalidate two U.S. patents on the company’s HIV medicine, and Chinese researchers applie...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.